Company Overview and News

5
MB Financial, Inc. Receives Necessary Stockholder Approvals for Merger with Fifth Third Bancorp

11h globenewswire
CHICAGO, Sept. 18, 2018 (GLOBE NEWSWIRE) -- MB Financial, Inc. (the “Company”) (NASDAQ: MBFI) announced today that it received the requisite approvals of its common stockholders for the Company’s pending merger with Fifth Third Bancorp (“Fifth Third”) at a special meeting of the Company’s stockholders held today. Detailed voting results will be provided in a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission within the next four business days.
MBFI FITB MBFIP FITBI

8
7 Big Bank Stocks That Are Breaking Down

2018-09-12 investorplace
U.S. equities are suffering another bout of weakness on Wednesday, falling into negative territory after a big intraday reversal pushed the Dow Jones Industrial Average back below the 26,000 level. The catalyst, as you may have guessed, was more fears on the trade front. Reports are crossing that adding Canada to the recently penned bilateral trade deal between the United States and Mexico could be more difficult than previously believed.
BPFH MBFI CHFN CFG USB CFIN BPFHW STI CIWV STI-A BPFHP STL FITB CSFL SBT

5
FITB / Fifth Third Bancorp 425 (Prospectus)

2018-09-12 sec.gov
425 Filed by Fifth Third Bancorp pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securi
FITB

5
FITB / Fifth Third Bancorp 425 (Prospectus)

2018-09-12 sec.gov
425 Filed by Fifth Third Bancorp pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securi
FITB

5
FITB / Fifth Third Bancorp 425 (Prospectus)

2018-09-12 sec.gov
425 Barclays Global Financial Services Conference 2018 Greg D. Carmichael Chairman, President & Chief Executive Officer September 12, 2018 Filed by Fifth Third Bancorp pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: MB Financial, Inc. SEC File No.: 001-36599 Filer’s SEC File No.: 001-33653 Date: September 12, 2018
FITB

5
FITB / Fifth Third Bancorp 425 (Prospectus)

2018-09-12 sec.gov
425 Barclays Global Financial Services Conference 2018 Greg D. Carmichael Chairman, President & Chief Executive Officer September 12, 2018 Filed by Fifth Third Bancorp pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: MB Financial, Inc. SEC File No.: 001-36599 Filer’s SEC File No.: 001-33653 Date: September 12, 2018
FITB

5
FITB / Fifth Third Bancorp FORM 8-K (Current Report)

2018-09-11 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
FITB

5
FITB / Fifth Third Bancorp null

2018-09-02 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0T(# @;V)J#3P\+TQI;F5A(F
FITB

5
FITB / Fifth Third Bancorp null

2018-09-02 sec.gov
CORRESP [Fifth Third Bank Letterhead] August 2, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporate Finan
FITB

5
MB Financial, Inc. Announces Schedule for Third Quarter 2018 Earnings Release

2018-08-23 globenewswire
CHICAGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- MB Financial, Inc., (Nasdaq: MBFI) today announced it expects to release its third quarter 2018 earnings at approximately 6:00 a.m. Eastern Time on Tuesday, October 23, 2018. In light of the pending merger with Fifth Third Bancorp, the Company will not be hosting an earnings call.
MBFI FITB MBFIP FITBI

16
JPMorgan to Lay Off Employees in Asset Management Division

2018-08-23 zacks
Following an internal review, JPMorgan (JPM - Free Report) intends to terminate nearly 100 employees in its Asset Management division. This was first reported by Wall Street Journal. Later on, the bank’s spokeswoman, Kristen Chambers confirmed the news. In an e-mail she said, “We routinely review our coverage model to ensure appropriate staffing levels across a variety of functions. Any reductions will be relatively small and will not affect our continued investment in client coverage and our business.
WFC WFCNP SOJA STZ.B SO STZ FITBI FITB 3772

12
Fifth Third (FITB) Displays Revenue Strength: Time to Hold?

2018-08-23 zacks
The Finance sector turned out to be one of the best performers in the April-June quarter. Specifically, benefits from a stabilizing economy and improving interest-rate scenario have well positioned the banking industry. Also, lower commercial tax rates are likely to boost banks’ profitability further. In addition, relieving banks from some of the stringent requirements of the Dodd-Frank Act has made the companies optimistic of future earnings growth and raised investor sentiment as well.
SOJA STZ.B SO STI CMA FITB STZ FITBI CMPWW

5
Comerica: A Good Play On Higher Interest Rates

2018-08-21 seekingalpha
Comerica (CMA) is one of the banks with higher asset sensitivity to interest rates, being therefore a very good growth play within the banking sector right now.
STI CMA STI-A DTK FITB 3772 FITBI CMPWW

5
FITB / Fifth Third Bancorp null

2018-08-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A
FITB

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

18h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

19h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

21h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to FITB / Fifth Third Bancorp on message board site Silicon Investor.

FITBIT - tell us about your device FITBIT - tell us about your device FITBIT - tell us about your device FITB (Fifth Third Bancorp) FITB (Fifth Third Bancorp) FITB (Fifth Third Bancorp)
Hometown Auto (HCAR) - an internet/web play - profitbl co. Hometown Auto (HCAR) - an internet/web play - profitbl co. Hometown Auto (HCAR) - an internet/web play - profitbl co.
CUSIP: 316773100